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Background: Giant-cell arteritis (GCA) is considered a T helper (Th)1- and Th17-
mediated disease. Interleukin (IL)-12 is a heterodimeric cytokine (p35/p40) involved in 
Th1 differentiation. When combining with p19 subunit, p40 compose IL-23, a powerful 
pro-inflammatory cytokine that maintains Th17 response.
Objectives: The aims of this study were to investigate p40, p35, and p19 subunit 
expression in GCA lesions and their combinations to conform different cytokines, to 
assess the effect of glucocorticoid treatment on subunit expression, and to explore func-
tional roles of p40 by culturing temporal artery sections with a neutralizing anti-human 
IL-12/IL-23p40 antibody.
Methods and results: p40 and p19 mRNA concentrations measured by real-time 
RT-PCR were significantly higher in temporal arteries from 50 patients compared to 20 
controls (4.35 ± 4.06 vs 0.51 ± 0.75; p < 0.0001 and 20.32 ± 21.78 vs 4.17 ± 4.43 
relative units; p <  0.0001, respectively). No differences were found in constitutively 
expressed p35 mRNA. Contrarily, p40 and p19 mRNAs were decreased in temporal 
arteries from 16 treated GCA patients vs those from 34 treatment-naïve GCA patients. 
Accordingly, dexamethasone reduced p40 and p19 expression in cultured arteries. 
Subunit associations to conform IL-12 and IL-23 were confirmed by proximity-ligation 
assay in GCA lesions. Immunofluorescence revealed widespread p19 and p35 expres-
sion by inflammatory cells, independent from p40. Blocking IL-12/IL-23p40 tended 
to reduce IFNγ and IL-17 mRNA production by cultured GCA arteries and tended to 
increase Th17 inducers IL-1β and IL-6.
conclusion: IL-12 and IL-23 heterodimers are increased in GCA lesions and decrease 
with glucocorticoid treatment. p19 and p35 subunits are much more abundant than 
p40, indicating an independent role for these subunits or their potential association with 
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alternative subunits. The modest effect of IL-12/IL-23p40 neutralization may indicate com-
pensation by redundant cytokines or cytokines resulting from alternative combinations.
Keywords: giant-cell arteritis, Th1/Th17 cytokines, il-12/23 p40, il-23p19, il-12p35, glucocorticoid, biologic 
therapies
inTrODUcTiOn
Giant-cell arteritis (GCA) is a granulomatous vasculitis involv-
ing large and medium sized-arteries in aged individuals (1, 2). 
Glucocorticoids remain the cornerstone of remission-induction 
in GCA. However, about 40–60% of patients relapse when 
glucocorticoids (GC) are tapered (3–5). Recently, randomized 
controlled trials have indicated that inhibiting T-cell activation 
with abatacept (6) and, particularly, blocking interleukin (IL)-6 
receptor with tocilizumab are effective in maintaining gluco-
corticoid-induced remission (7, 8). However, not all patients 
respond indicating an unmet need for a better understanding 
of the hierarchy and contribution of additional pathogenic 
pathways in GCA.
Giant-cell arteritis has been classically considered a T helper 
(Th)1-mediated disease based on the presence of granulomas and 
the expression of interferon (IFN)γ and IFNγ-induced products 
in the arterial lesions (9–14). However, data generated in recent 
years indicate that Th17-mediated mechanisms also play a signifi-
cant role in GCA (14–17).
IL-12 and IL-23 are cytokines mainly produced by dendritic 
cells and macrophages that regulate the development of Th1 and 
Th17 responses, respectively. IL-12 is a heterodimeric cytokine 
composed by two subunits, p35 and p40, with a seminal role in 
Th1 differentiation and IFNγ production. The IL-12p40 subunit 
may also interact with p19 to conform IL-23, a crucial cytokine 
in maintaining and expanding Th17 differentiation (18). The 
observation that IL-12/23p40-deficient mice were resistant to 
experimentally induced autoimmune diseases suggested that 
IL-12 and IL-23 play a major role in triggering or maintaining 
chronic inflammatory diseases (19). According to these models, 
IL-23 might have a more prominent pro-inflammatory role since 
IL-12p35-deficient mice may show exacerbated disease (19–22). 
Currently, several therapeutic agents targeting IL-12, IL-23, or 
IL-17 are being tested in clinical trials for a variety of immune-
mediated diseases (23).
Preliminary studies have shown that IL-12/23p40, IL-12p35, 
and IL-23p19 subunits are expressed in GCA lesions (24, 25), 
but their relative expression, combinations and functions have 
not been addressed. Interestingly, IL-12/23p40 but not IL-12p35 
expression was increased in temporal artery biopsies from 
patients with relapsing GCA after 1 year of treatment (25), indi-
cating independent functions for both subunits and suggesting a 
role for IL-23 in persistent disease activity (25).
The aims of this study were to investigate IL-12/23p40, 
IL-12p35, and IL-23p19 subunit expression in GCA lesions and 
their combination to conform different cytokines, to investigate 
the effect of glucocorticoid treatment on subunit expression, to 
analyze the relationship between subunit expression and glu-
cocorticoid requirements, and to explore IL-12/23p40 function 
in GCA by exposing temporal artery sections to a neutralizing 
anti-human IL-12/IL-23p40 antibody.
MaTerials anD MeThODs
Patients
The study group consisted of 50 patients with biopsy-proven 
GCA diagnosed between 1997 and 2006 at our institution 
(Hospital Clinic, Barcelona). All patients were prospectively 
evaluated and treated by the authors (Georgina Espígol-
Frigolé, Jose Hernández-Rodríguez, Sergio Prieto-González, 
and Maria C. Cid) with a predefined glucocorticoid-tapering 
schedule (4, 26). Patients received an initial prednisone dose of 
1 mg/kg per day (up to 60 mg/day) for 1 month. Intravenous 
methylprednisolone pulse therapy (1  g daily for 3  days) was 
initially administered to patients with recent (<48 h) visual loss. 
Prednisone was subsequently tapered at 10  mg/week. When 
reaching 20  mg/day, this dose was maintained for 1–2  weeks 
and then reduced to 15  mg/day, which was maintained for 
1 month. A further reduction to a maintenance dose of 10 mg/
day was attempted. If tolerated, a reduction to 7.5 mg/day was 
tried after 3–6 months. A reduction to 5 mg/day was attempted 
approximately 3–6  months later and maintained for 1  year, 
after which a reduction of 1.25  mg/day was preformed every 
6 months. Methotrexate at 15 mg/week was added when patients 
experienced ≥2 relapses or had developed GC side effects. If 
relapses occurred, prednisone dose was increased by 10–15 mg/
day above the previous effective dose.
Clinical data recorded included disease symptoms at the time 
of diagnosis, number of relapses, and time to complete prednisone 
discontinuation with no relapse within the following 6 months. 
Relapse was defined as reappearance of cranial symptoms, poly-
myalgia rheumatica, systemic symptoms, or anemia that could 
not be attributed to other conditions, usually accompanied by a 
rebound in erythrocyte sedimentation rate (ESR) or C-reactive 
protein (CRP) (4, 27). Isolated fluctuations on ESR or CRP were 
not considered relapses.
Clinical data of the patients are displayed in Table S1 in 
Supplementary Material. Thirty-six patients were treatment-
naïve and 14 had received prednisone (1 mg/kg/day) for a median 
of 7 days (range 2–12) before the performance of temporal artery 
biopsy. Uninvolved temporal arteries from 20 patients (14 women 
and 6 men) with a median of 77 years (range 64–91) in whom 
GCA was considered but not confirmed, served as controls. 
Final diagnoses of these patients are depicted in Table S2 in 
Supplementary Material.
This study was carried out in accordance with the recommen-
dations of the Ethics Committee of Hospital Clínic (Barcelona), 
with written informed consent from all subjects. All subjects gave 
written informed consent in accordance with the Declaration of 
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Helsinki. The study was approved by the Ethics Committee of 
Hospital Clínic (Barcelona).
rna isolation and cDna synthesis
Temporal artery biopsies were embedded in optimal cutting tem-
perature (OCT, Sakura, The Netherlands), snap-frozen in liquid 
nitrogen, and stored at −80°C. Total RNA was obtained from 
tissue with TRIzol Reagent (Invitrogen, Thermo Fisher Scientific, 
Waltham, MA, USA). RNA (1  µg) was reverse-transcribed to 
cDNA using the High Capacity cDNA Reverse Transcription kit 
(Applied Biosystems, Foster City, CA, USA).
real-Time Quantitative Pcr
cDNA was measured by quantitative real-time PCR using 
specific Pre-Developed TaqMan gene expression assays from 
Applied Biosystems using the following probes: Hs01073447_m1 
(IL-12p35), Hs01011518_m1 (IL-12p40), Hs00372324_m1 
(IL-23p19), Hs00989291_m1 (IFNγ), Hs00171138_m1 (CXCL11), 
Hs00171042_m1 (CXCL10), Hs00171065_m1 (CXCL9), 
Hs00174383_m1 (IL-17), Hs00174131 (IL-6), Hs01555410_m1 
(IL-1β), and Hs02621508_m1 (tumor necrosis factor, TNFα). All 
samples were normalized to the expression of the housekeeping 
gene, GUSb. The comparative CT method was used to assess 
relative gene expression. Results were expressed as relative units.
Measurement of circulating il-12,  
il-12p40, and il-23p19
Plasma citrate from the 50 GCA patients was obtained at the time 
of diagnosis before the initiation of glucocorticoid therapy and 
frozen at −80°C. Plasma from 20 age- and sex-matched healthy 
donors was obtained for comparison. Human heterodimer IL-12 
and IL-12/23p40 subunit were measured in plasma by immuno-
assay (Quantikine ELISA kits from R&D Systems, Minneapolis, 
MN, USA). To quantify plasma IL-23, Abcam kit (Cambridge, 
UK) detecting the IL-23p19 subunit was employed. Procedures 
were performed according to the manufacturer’s protocol.
immunofluorescence staining  
and confocal Microscopy
For qualitative assessment of cytokine distribution at the cel-
lular level, immunofluorescence staining was performed in 
six temporal artery biopsies obtained from four patients and 
two controls. Temporal artery fragments were fixed in cold 4% 
paraformaldehyde (PFA) in phosphate-buffered saline (PBS), 
cryo-protected in increasing concentrations of saccharose (15 
and 30%), embedded in OCT, and frozen at −80°C. Slides with 
10-µm cryostat sections were further fixed with 4% paraform-
aldehyde for 10 min at room temperature, washed in PBS, and 
soaked in PBS with 0.1% Triton, 1% bovine serum albumin, and 
5% donkey serum (Sigma-Aldrich, St. Louis, MO, USA) for 1 h 
at 4°C. Sections were incubated at 4°C overnight with the follow-
ing primary antibodies: human IL-12 p35 (mouse monoclonal, 
Acris-Antibodies, Herford, Germany) at 1:100 dilution, human 
IL-23p19 (rabbit polyclonal, Abcam) and human IL-12p40 (goat 
polyclonal, Santa Cruz Biotechnology, Dallas, TX, USA), both at 
1:50 dilution, and incubated overnight at 4°C.
Slides were washed in PBS (5 min, three times), followed by incu-
bation with secondary antibodies (spectrally distinct Alexa Fluor-
conjugated antibodies to goat, mouse and rabbit IgG; Molecular 
Probes, Thermo Fisher Sicentific). Nuclei were visualized with 
Hoechst. Slides were mounted with Prolong Gold Antifade Reagent 
(Molecular Probes, Thermo Fisher Sicentific) and examined 
using a laser scanning confocal Leica TCS SP5 microscope (Leica 
Microsystems, Heidelberg, Germany). Images were processed with 
Image J software (Wayne Rasband, Bethesda, MD, USA).
Proximity ligation assay (Pla)
Proximity ligation assay was used to visualize close colocaliza-
tion (<40 nm) of p40 and p19 subunits (IL-23) and p40 and p35 
subunits (IL-12), respectively, in temporal artery biopsies using 
Duolink Detection kit (Olink Bioscience). Tissues were fixed (4% 
PFA for 20 min at room temperature). After 1-h incubation in 
blocking buffer (0.1% Triton X-100, 5% FBS 1% BSA in PBS) at 
room temperature, slides were incubated overnight at 4°C with 
anti-human p19 rabbit polyclonal Ab (2 µg/ml, Sigma-Aldrich) 
and anti-human p40 goat polyclonal Ab (10 μg/ml, Santa Cruz 
Biotechnology) in blocking buffer or alternatively with anti-
human p35 rabbit poyclonal Ab (5 µg/ml Atlas, Bromma, Sweden) 
and anti-human p40 goat polyclonal Ab (10 µg/ml Santa Cruz 
Biotechnology). After two washes (5 min duration) in wash buffer 
(0.1 M Tris–HCl pH 7.5, 0.5 M NaCl, 5% Tween-20 in ultrapure 
water), slides were incubated (30 min at 37°C) with PLA probe 
solution containing anti-rabbit MINUS and anti-goat PLUS 
Duolink PLA probes. After washing, circularization and ligation 
of the oligonucleotides in the probes, an amplification step was 
performed using polymerase solution (100 min at 37°C). After 
washing and re-fixation in 4% PFA, the slides were mounted with 
Duolink II Mounting medium containing DAPI and examined 
using a laser scanning confocal Leica TCS SP5 microscope (Leica 
Microsystems, Heidelberg, Germany). Images were processed 
with Image J software (Wayne Rasband, Bethesda, MD, USA).
Temporal artery culture
Temporal artery sections from 10 GCA patients and 10 controls 
were embedded in Matrigel to ensure prolonged survival and 
cultured ex vivo as described (10, 11, 28, 29) with or without neu-
tralizing anti-human IL-12p40 mouse monoclonal Ab (10 μg/ml 
R&D Systems), or dexamethasone (DXM) (0.5  µg/ml, Sigma-
Aldrich). Each condition was tested in three replicate wells. 
Biopsies were frozen in TRIzol reagent for RNA extraction.
statistical analysis
Mann–Whitney test, Spearman correlation, and Kaplan–Meier 
survival curves analyzed with log-rank test were used for statisti-
cal analysis using SPSS software, version PASW 18.0.
resUlTs
il-12/23p40 and il-23p19 expression is 
increased in Temporal arteries From 
Patients With gca
As shown in Figures 1A,B, IL-12/23p40 mRNA and IL-23p19 
mRNA concentrations were significantly increased in temporal 
FigUre 1 | IL-12/23p40, IL-12p35, and IL-23p19 concentrations in temporal artery biopsies (mRNA) and in serum from patients with giant-cell arteritis (GCA). 
(a) IL-12/23p40 mRNA, (B) IL-23p19 mRNA, and (c) IL-12p35 mRNA expression (relative units) in temporal artery biopsies from 36 treatment-naïve patients and 20 
controls. (D) IL-12/23p40 concentration in sera from 36 treatment-naïve patients and 19 controls.
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arteries from untreated patients compared to control arter-
ies (4.35 ±  4.06 vs 0.51 ±  0.75 relative units; p <  0.0001 and 
20.32 ± 21.78 vs 4.17 ± 4.43 relative units; p < 0.0001, respectively). 
By contrast, no significant differences were found in IL-12p35 
mRNA expression between patients and controls (14.95 ±  8.9 
vs 20.36 ± 14.93, p = 0.076) (Figure 1C). IL-12/23p40 mRNA 
expression in untreated GCA arteries significantly correlated 
with IL-12p35 (r =  0,430, p =  0.01) and IL-23p19 (r =  0,431, 
p = 0.01).
Plasma IL-12 and IL-23 heterodimeric cytokines were 
not detectable or were around the detection threshold both 
in patients and controls (data not shown). Although plasma 
IL-12/23p40 subunit was measurable, no significant differences 
between patients and controls were observed (130 ±  95.25 vs 
115 ± 50.61 pg/ml; p = 0.941) (Figure 1D).
To assess expression of IL-12/23p40, IL-12p35, and IL-23p19 
subunits at the protein level and their distribution in temporal 
arteries, immunofluorescence staining was performed. IL-12p35 
had constitutive expression in the muscular layer from normal 
arteries in accordance with the remarkable IL-12p35 mRNA 
concentration found in control arteries (Figure  2A). However, 
IL-12p35 distribution changed in GCA-involved arteries: as the 
medial layer was damaged, muscular IL-12p35 decreased and 
it was mainly expressed by infiltrating leukocytes (Figure  2B). 
IL-12p40 and IL-23p19 protein expression was virtually unde-
tected in normal arteries (Figures 2C,E) and clearly increased in 
GCA-affected arteries, mostly at the expenses of inflammatory 
cells (Figures 2D,F). Interestingly, intense p19 or p35 expression 
by inflammatory cells, independent from p40, could be observed 
and p19 and p35 were more abundant than p40 (Figure  2). 
Although p35 and p19 expression exceeded that of p40, associa-
tion between subunits p40 and p35 or p40 and p19 to conform 
IL-12 and IL-23, respectively, could be confirmed by PLA in GCA 
lesions and barely in control arteries (Figure 3).
il-12/23p40 and il-23p19 expression  
is Decreased in Temporal arteries From 
glucocorticoid-Treated gca Patients
IL-23p19 mRNA concentrations in temporal artery biopsies from 
treated GCA patients were significantly lower than those found 
in treatment-naïve GCA patients (7.87 ± 8.04 vs 20.32 ± 21.78 
FigUre 2 | Immunofluorescence detection of IL-12/23p40, IL-12p35, and IL-23p19 subunit expression in temporal artery lesions. (a) IL-12p35 staining (blue) in a 
temporal artery from a control individual showing almost selective expression in the media layer. Nuclei were stained with Hoechst (white). (B) IL-12p35 expression in 
GCA-involved temporal artery section, predominantly in inflammatory infiltrates. (c,D) Negative IL-23p19 immunostaining (green) in sections of normal temporal 
arteries (c) and intense expression in GCA samples (D) where IL-23p19 expression can be observed in all arterial layers especially in the most inflamed areas.  
(e) Lack of IL-12/23p40 immunostaining in a temporal artery from a control. (F) Detection of IL-12/23p40 expression (red) in a GCA-involved temporal artery section 
predominantly in the adventitial layer. (g,h) IL-12p35 (blue), IL-23p19 (green) and IL-12/23p40 (red) staining merge in a temporal artery section from a control and 
from a GCA patient, respectively. Pictures are representative of four arteries from four GCA patients and two controls, and at least three sections per sample were 
evaluated.
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relative units; p  =  0.010) (Figure  4A). IL-12/23p40 mRNA 
concentrations also tended to be reduced in treated patients 
(2.30 ± 3.39 vs 4.35 ± 4.06 relative units; p = 0.065) but differences 
did not reach statistical significance (Figure 4B). No differences 
were found in IL-12p35 mRNA between both groups (16.57 ± 8.9 
vs 14.95 ± 8.9 relative units; p = 0.183) (Figure 4C).
The effect of glucocorticoids in reducing p40 and p19 expres-
sion was confirmed in cultured temporal arteries from patients 
with GCA. As with freshly stained arteries, IL-12/IL-23 p40 
and IL-23p19 subunits tended to be more abundant in cultured 
arteries from patients with GCA than in those obtained from con-
trols, although differences did not reach statistical significance, 
probably due to the small sample size and remarkable individual 
variability. DXM significantly reduced p19 mRNA and tended to 
decrease p40 expression (Figures 4D,E).
lack of correlation Between il12/23p40, 
il12p35, and il23p19 mrna expression 
and gca clinical Findings
As shown in Table S3 in Supplementary Material, no differences 
in IL-12/23p40 or IL-12p35 mRNA expression according to clini-
cal findings could be observed. A trend toward higher expres-
sion of IL23p19 mRNA was observed in patients with systemic 
symptoms (fever or weight loss) (41.46 ±  12.7 vs 17.79 ±  3.7 
relative units, p = 0.055) but the difference did not reach statisti-
cal significance.
il-12/23p40, il-12p35, and il-23p19 
expression and long-Term response to 
glucocorticoid Treatment
Patients with elevated IL-12/23p40 mRNA content (above 75% 
percentile) in their artery lesions were able to completely withdraw 
prednisone earlier than patients with lower IL-12/IL-23p40mRNA 
levels (p  =  0.022) (Figure  5A). Similarly, patients with high 
IL-23p19 mRNA tended to tolerate prednisone discontinuation 
earlier than those with lower IL-23p19 RNA values (p = 0.104) 
(Figure  5B). No differences were found between patients with 
high or low levels of IL-12p35 in terms of glucocorticoid treat-
ment duration (Figure 5C). Accordingly, IL-12/IL-23p40 mRNA 
levels were significantly higher in patients able to completely 
discontinue prednisone at 3 years (7.37 ± 2.25 vs 4.29 ± 4.58 rela-
tive units; p = 0.016) (Figure 5D). No significant differences were 
found in IL-12p35 and IL-23p19 mRNA concentrations between 
patients requiring or not prednisone at 3  years (20.8 ±  10.54 
vs 14.07 ±  8.74 relative units; p =  0.065 and 29.59 ±  25.72 vs 
15.03 ± 11.25 relative units; p = 0.084, respectively) (Figures 5E,F). 
However, there were no significant differences in IL-12/23p40, 
IL-12p35, and IL-23p19 mRNA levels in temporal arteries from 
patients who achieved sustained remission compared with those 
who presented relapses (4.42 ± 4.3 vs 5.04 ± 4.21 relative units; 
p = 0.516, 15.25 ± 9.46 vs 16.63 ± 9.93 relative units; p = 0.682, 
20.88 ± 21.59 vs 21.79 ± 22.32 relative units; p = 0.616, respec-
tively) (Table S4 in Supplementary Material).
FigUre 3 | Coexpression of subunits to conform IL-12 and IL-23 in temporal artery lesions from patients with GCA. (a) Close-up view of a GCA-involved artery 
where IL-12p35 + cells (blue) can be observed predominantly in media layer, IL-23p19 + cells (green) in all arterial layers and IL-12/23p40 + cells (red) in the 
adventitia. (B) Higher magnification of inflammatory cells expressing IL-12/23p40 (red), (c) IL-23p19 (green), and (D) merge showing expression of IL-23 (orange, 
indicated by arrows). (e) Higher magnification of inflammatory cells expressing IL-12/23p40 (red), (F) IL12p35 (blue), and (g) merge showing expression of IL-12 
(purple, indicated by arrows). The temporal arteries were subjected to proximity ligation assay (PLA) to determine proximity of IL-12 and IL-23 subunits. The red 
staining marks the colocalization (<40 nm) of IL-12/23p40 and IL-12p35 (IL-12). Blue (Hoechst) marks the cell nuclei. (h) Negative PLA signalfor colocalization of 
IL-12/23p40 and IL-12p35 (IL-12) in a control artery. Minimal autofluorescence of the elastic lamina can be appreciated (i). Positive colocalization of IL-12/23p40 
and IL-12p35 (IL-12) in a GCA-affected temporal artery. The boxed area is magnified on the right (J). (K) Negative PLA signal for colocalization of IL-12/23p40 and 
IL-23p19 (IL-23) in a control artery. Minimal autofluorescence of the elastic lamina can be appreciated (l) Colocalization of IL-12/23p40 and IL-23p19 (IL-23) in a 
positive GCA temporal artery. The boxed area is magnified on the right (M).
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effect of neutralizing il-12/23p40 subunit 
in cultured Temporal arteries From 
Patients With gca
In order to elucidate potential functions of the IL-12/23p40 subu-
nit in GCA, we investigated the effects of blocking IL-12/23p40 
with a neutralizing monoclonal antibody in ex vivo cultured 
temporal artery biopsies. Several molecules related to Th1 and 
Th17 differentiation were investigated (9, 11, 30). Neutralization 
of IL-12/IL-23p40 tended to decrease IFNγ mRNA and, slightly, 
IFNγ-induced chemokine CXCL11 and CXCL10, but not 
CXCL9, mRNAs in cultured arteries. IL17 mRNA also tended 
to decrease and no apparent effect on TNFα expression was 
observed. Conversely IL-6 and IL-1β mRNA involved in Th17 
differentiation tended to increase, possibly as a compensatory 
mechanism (Figure  6). As shown in the same figure, DXM 
significantly reduced IFNγ, CXCL10, IL-17, IL-6, and IL-1β and 
tended to reduce CXCL9 and TNFα.
DiscUssiOn
IL-12/23p40 and IL-23p19 expression was significantly increased 
in GCA lesions, confirming preliminary observations obtained 
from small series of patients (24, 25). By contrast, IL-12p35 
mRNA expression was similar between patients and controls. 
However, in normal arteries, IL-12p35 was primarily expressed 
by vascular smooth muscle cells (VSMC) whereas in GCA arter-
ies, where substantial damage and loss of VSMC frequently occur, 
IL-12p35 was mostly expressed by inflammatory cells. Similar 
FigUre 4 | Decreased IL-12/23p40 and IL-23p19 expression in temporal arteries from treated GCA patients. IL-23p19 (a), IL-12/23p40 (B), and IL-12p35 (c) 
expression (relative units) in temporal arteries from 36 treatment-naïve and 14 prednisone-treated GCA patients. (D) mRNA IL-12/23p40 expression and (e) mRNA 
IL-23p19 expression on cultured biopsies (negative and GCA), showing the effect of dexamethasone (DXM) in GCA arteries. Bars represent mean ± SEM.
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changes in distribution between normal and inflamed arteries 
have been observed in other molecules expressed by both VSMC 
and infiltrating leukocytes (29, 31). Expression of IL-12p35, 
IL-12/23p40, and IL-23p19 subunits suggest that IL-12 and 
IL-23 heterodimers are present in GCA lesions. By PLA we could 
demonstrate, indeed, colocalization of the IL-12/IL-23p40 and 
IL-12p35 subunits configuring IL-12 and colocalization of IL-12/
IL-23p40 and IL-23p19 subunits conforming IL-23 in GCA, sup-
porting the participation of both Th1 and Th17 differentiation 
pathways in the development of arterial inflammation. However, 
IL-12/23p40 expression was low, compared to its partners IL-12/
p35 or IL-23p19 which were remarkably more abundant. This 
may explain why initial attempts using less sensitive methods 
concluded that there was no IL-12/23p40 expression in GCA 
(32). Distribution of lesions was also dissociated: while IL-23p19 
and IL-12p35 subunits were detected in all arterial layers, 
IL-12/23p40 was mainly found in the adventitia. Consequently, 
our results indicate that, in GCA, p19 and p35 can be expressed 
independently from p40 being also part of heterodimeric 
cytokines other than IL-23 or IL-12, that could be also present 
in GCA lesions. Accordingly, increased expression of IL-23p19 
exceeding the relatively low levels of bioactive IL-23 has also been 
detected in the rheumatoid synovium (33).
The IL-12/IL-6 family of cytokines resulting from different 
combinations of alpha (p28, p35, p19) and beta [p40, Ebstein-
Barr induced 3 (EBi3)] subunits is currently expanding (34). 
Recently, a novel IL-12 family pro-inflammatory member named 
IL-39 composed by IL23p19 and EBi3 and secreted by lipopol-
ysaccharide-stimulated B lymphocytes has been described (34, 
35). Moreover IL-12p35 may combine with EBi3 to conform 
IL-35, a putatively suppressive cytokine produced by regulatory 
T lymphocytes (34, 36). Adding complexity, some subunits may 
be individually functional without interaction with partner 
subunits: we have recently demonstrated that IL-23p19, but not 
IL-12/23p40, can be expressed by endothelial cells exposed to 
inflammatory stimuli. Endothelial p19 has a p40-independent 
role as an intracellular activator of endothelial cells, by directly 
interacting with endothelial gp130 and leading to phosphoryla-
tion of signal transducer and activator of transcription3 (37). As 
observed in GCA, IL-23p19 mRNA is more abundant than 
FigUre 5 | IL-12/23p40, IL-12/23p19, and IL-12p35 mRNA expression in lesions and long-term response to therapy. Percentage of treatment-naïve GCA patients 
requiring prednisone treatment over time, according to the intensity of IL-12/23p40 (a), IL-12/23p19 (B), and IL-12p35 (c) mRNA expression, in temporal artery 
lesions. High refers to mRNA levels above the 75th percentile (N = 26), and low below the 75th percentile (N = 10). IL-12/23p40 (D), IL-23p19 (e), and IL-12p35 (F) 
mRNA concentrations in initial temporal artery biopsies from patients still requiring prednisone (N = 12) compared with patients in sustained remission (N = 24), 
3 years after diagnosis.
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IL-12/IL-23p40 mRNA in cultured macrophages (18), raising 
the possibility that p19 may play independent functional roles 
even in cells such as macrophages able to secrete mature, heter-
odimeric, IL-23.
Although both IL-12/and IL-23 were increased in lesions, 
mature IL-12 and IL-23 were barely detectable in plasma suggest-
ing that functional activities of these cytokines are predominantly 
local. IL-12/23p40 subunit, which is known to form homodimers 
with a presumed counter-regulatory role (34, 38) was present in 
plasma but with no significant differences between patients and 
controls. Contrarily to other cytokines such as TNFα or IL-6 
which have systemic effects (30), and consistent with the local 
paracrine effects of IL-12 and IL-23 subunits, there was no sig-
nificant relationship between their tissue expression and disease 
manifestations.
IL-12/23p40 and, particularly, IL-23p19 were reduced in 
biopsies from treated patients in accordance with our previous 
results in a small series (25). Moreover, downregulation by 
glucocorticoids was confirmed in cultured arteries. Interestingly, 
patients with strong initial expression of IL-12/23p40 were able to 
discontinue prednisone treatment earlier than patients with low 
IL-12/23p40 expression and IL-12/23p19 followed a similar trend. 
Given that IL-23 is essential for the expansion and homeostasis of 
Th17 cells (39, 40), this finding is consistent with a previous study 
where we found that a strong IL-17A expression was associated 
with more sustained response to glucocorticoids, suggesting that 
patients who develop a predominantly Th17 response are more 
sensitive to glucocorticoid treatment (17). Downregulation of 
these pro-inflammatory cytokines may partially account for the 
therapeutic relief provided by glucocorticoids.
Although not highly expressed in lesions, IL-12/23 p40 
may be relevant to vascular inflammation in large-vessel vas-
culitis. Recently, a meta-analysis of massive genotyping studies 
performed with GCA and Takayasu arteritis patients showed 
that a variant in close proximity to the IL-12B gene (encoding 
for IL12/23p40) is associated with increased genetic risk for 
both diseases, although the putative functional impact of this 
variant on IL-12B expression remains unknown (41). A recent 
open-label trial with ustekinumab, a monoclonal antibody 
neutralizing IL-12/23p40, suggests benefit in a small series of 
patients with refractory/relapsing GCA (42). Analysis of the 
peripheral blood compartment revealed reduction in both Th1 
and Th17 polarization in a patient with GCA upon ustekinumab 
treatment (43). However, when we analyzed the effects of 
FigUre 6 | Changes in gene expression by blocking IL-12/23p40 on cultured GCA biopsies. mRNA concentrations of IFNγ, CXCL11, CXCL10, CXCL9, IL-17,  
IL-6, IL-1β, and tumor necrosis factor α in 10 cultured control arteries (negative biopsies, Neg Bx) vs 10 cultured GCA-involved arteries untreated or exposed to 
anti-human IL-12p40 mouse monoclonal Ab (anti-p40) (10 µg/ml), or dexamethasone (DXM) (0.5 µg/ml). Statistical comparisons were performed between 
histologically negative and GCA-involved arteries and between GCA-involved arteries and anti-p40 treated and DXM treated. Bars represent mean ± SEM, 
*p < 0.05.
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blocking IL-12/23 p40 on involved tissue from GCA patients, 
only a trend, consistent with its known biology, was observed. 
IL-12/23p40 inhibition tended to reduce IFNγ expression as 
well as expression of IFNγ induced chemokines CXCL10 and 
11 but not CXCL9. IL-12/23p40 blockade slightly reduced 
IL-17 expression although, interestingly, cytokines involved in 
Th17 differentiation such as IL-1β and IL-6 increased, possibly 
as a compensatory mechanism. Effects in tissue may be more 
complex than those observed in the peripheral compartment 
(43) and stimuli and interactions with other elements in the 
microenvironment may configure a protective niche. Although 
the inhibitory effect of the anti-IL-12/23p40 antibody used in 
our study may not be equivalent to that of ustekinumab, which 
has been generated for therapeutic purposes, recent studies sug-
gest that neutralizing IL-12/23p19 may have more potent effects 
than blocking IL-12/23p40 in suppressing inflammatory activity 
in other diseases (44).
Our functional ex vivo model has some limitations such as iso-
lation from a functional immune system or induction of changes 
by the culture itself in the expression of some inflammatory 
molecules (10). Moreover, lesions are often segmental in GCA 
arteries and this may have increased variability in responses. 
However, in spite of these limitations this model has been useful 
to evidence functional modifications after therapeutic interven-
tion with various agents, including biologic agents (10, 11).
The increasingly recognized diversity of subunits configuring 
the IL-12/IL-6 superfamily of cytokines to which IL-12 and IL-23 
belong, as well as the multiple potential partnership of subunits 
and receptor chains providing pro-inflammatory and anti-
inflammatory stimuli depending on the specific combinations, 
has added an unexpected complexity to this system (34). Our 
results clearly indicate that additional combinations to the clas-
sical heterodimers IL-12 and IL-23 may occur in GCA and may 
lead to incomplete or compensated responses to the blockade of 
single subunits.
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